Article

PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophages

2020-07-18

Abstract excerpt

<h4>ABSTRACT</h4> The majority of metastatic, castrate-resistant prostate cancer (mCRPC) patients are de novo resistant to immune checkpoint blockade (ICB), so therapeutic strategies to enhance immune-responsiveness are urgently needed. Here we performed a co-clinical trial of PARP inhibitor (PARPi) in combination with PD-1 or PDL-1 antibody in genomically unselected mCRPC patients or homologous-recombination pr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4cace4e7-fe1c-55c5-ac33-695cab696701
DOI: 10.1101/2020.07.17.198598

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophagesDOI 10.1101/2020.07.17.198598Read

Targeting of a STING Agonist to Perivascular Macrophages in Prostate Tumors Delays Resistance to Androgen Deprivation TherapySemantic proximity Read

MYC and p53 alterations cooperate through VEGF signaling to repress cytotoxic T cell and immunotherapy responses in prostate cancerSemantic proximity Read

PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation.Semantic proximity Read

PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage responseSemantic proximity Read

Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by sequential intermittent anti-PI3Kα/β/δ and anti-PD-1 treatmentSemantic proximity Read

Activation of Stimulator of Interferon Genes (STING): Promising Strategy to Overcome Immune Resistance in Prostate CancerSemantic proximity Read

Development of PARP inhibitors in advanced prostate cancerSemantic proximity Read

Castration-mediated IL-8 Promotes Myeloid Infiltration and Prostate Cancer ProgressionSemantic proximity Read

BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockadeSemantic proximity Read

SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression.Semantic proximity Read

PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF–caspase 8–GSDMD/E axis in ovarian cancerSemantic proximity Read

PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast CancerSemantic proximity Read